

Summary of Safety and Effectiveness

Sponsor:

Biomet, Inc.

Airport Industrial Park

P.O. Box 587

Warsaw, IN 46581-0587

Contact:

Dalene T. Binkley

Telephone: (219) 372-1612

Device:

Mallory/Head Lateralized Press-Fit Femoral

Classification: Hip joint metal/polymer semi-constrained porous uncemented prosthesis (CFR 888.3358).

Device Description: The Mallory/Head Lateralized Press-Fit Femoral sizes 8, 15, 16, and 17mm are an addition to the existing Mallory/Head Lateralized Press-Fit Femorals sizes 9-14mm. The additional stems maintain its predicate's design and material- Ti-6Al-4V (ASTM F-136). Because the stems are lateralized, like the predicate, the horizontal offset for the additional stems has been increased when comparing to the standard offset Mallory/Head Press-Fit Femoral (K921181). The horizontal offset is the distance from the center of a standard head to the center of the stem.

Indications for Use:

- 1) Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- 2) Rheumatoid arthritis
- 3) Correction of functional deformity
- 4) Treatment of non-union, femoral neck fracture, and throchanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.

Potential Risks: The potential risks associated with this device are the same as with any joint replacement device. These include, but are not limited to:

Reaction to bone cement Deformity of the joint Cardiovascular disease Fracture of the cement Implant loosening/migration Tissue growth failure

Blood vessel damage
Soft tissue imbalance
Delayed wound healing
Metal sensitivity
Fracture of the components

Bone fracture Infection Hematoma Dislocation Excessive wear

Nerve damage



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

NOV 3 0 2000

Ms. Dalene T. Binkley Regulatory Specialist Biomet Inc. Airport Industrial Park P.O.Box 587 Warsaw, Indiana 46581

Re: K003429

Trade Name: Malloy/Head Lateralized Press-Fit Femoral

Regulatory Class: II Product Code: LPH Dated: October31, 2000 Received: October 03, 2000

Dear Ms. Binkley:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Mak N Willerm Celia M. Witten, Ph.D., M.D.

Division of General, Restorative and

Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

510 (k) NUMBER (IF KNOWN): 1003429
DEVICE NAME: Mallory/Head® Lateralized Press-Fit Femoral
INDICATIONS FOR USE:
 Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis Rheumatoid arthritis Correction of functional deformity Treatment of non-union, femoral neck fracture, and throchanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use OR Over-The-Counter-Use (Per 21 CFR 801.109) (Optional Format 1-2-96) (Division Sign-Off) Division of General Restorative Devices 0 0 3 4 2 9

510(k) Number ____

Page___of ____